Anticoagulation therapy: Dabigatran and risk of myocardial infarction

Nature Reviews Cardiology

Volumn 9, Issue 5, 2012, Pages 260-262

  Eikelboom, John W ^a   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ARGATROBAN; DABIGATRAN; EFEGATRAN; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; PLACEBO; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; CLINICAL RESEARCH; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PATIENT CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STROKE; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; THROMBOEMBOLISM;

EID: 84859745039     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.34     Document Type: Short Survey

References (10)

1. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
2. Cairns, J. A., Connolly, S., McMurtry, S., Stephenson, M. & Talajic, M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can. J. Cardiol. 27, 74-90 (2011).
3. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A. & Wallentin, L. Newly identified events in the RE?LY trial. N. Engl. J. Med. 363, 1875-1876 (2010).
4. Uchino, K. & Hernandez, A. V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. http://dx.doi.org/10.1001/archinternmed.2011.1666.
5. Schulman, S. et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism [abstract O?TH?033]. J. Thromb. Hemost. 9 (Suppl. 2), 731 (2011).
6. Oldgren, J. et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur. Heart J. 32, 2781-2789 (2011).
7. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 359, 294-302 (2002).
8. Wallentin, L. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362, 789-797 (2003).
9. Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981-992 (2011).
10. Hohnloser, S. H. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE?LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial. Circulation 125, 669-676 (2012).